Oral Semaglutide Reduces Heart Events by 14% in High-Risk Diabetes Patients: SOUL Trial Analysis | Research

The takeaway

The SOUL trial demonstrated that oral semaglutide reduces major cardiovascular events by 14% versus placebo in high-risk type 2 diabetes patients, bringing GLP-1 heart protection to a pill form.

14% MACE reduction
First cardiovascular outcome trial to confirm heart protection with an oral GLP-1 drug, potentially making this benefit accessible to millions more patients

What the researchers found

The SOUL cardiovascular outcome trial demonstrated a 14% reduction in major adverse cardiovascular events (MACE) with oral semaglutide versus placebo in high-risk type 2 diabetes patients. This is the first CVOT to confirm cardiovascular protection with an oral GLP-1 receptor agonist, reinforcing the cardioprotective class effect of GLP-1RAs. The findings suggest improved accessibility for patient populations underrepresented in prior injection-based trials. However, gastrointestinal side effects and strict dosing requirements (taken on an empty stomach with minimal water) challenge long-term adherence.

Why it matters

Many patients who could benefit from GLP-1 drugs' cardiovascular protection avoid them because of the injection requirement. An oral formulation that provides the same heart protection could dramatically expand access. The 14% MACE reduction with a pill form means patients can get meaningful cardiovascular risk reduction without needles — a significant advance for medication adherence and health equity, particularly in primary care settings where injectable therapies are less commonly prescribed.

How the study worked

Perspective article analyzing the results and implications of the SOUL trial — a randomized, placebo-controlled cardiovascular outcome trial of oral semaglutide in high-risk type 2 diabetes patients. The article contextualizes SOUL within the broader landscape of GLP-1RA cardiovascular outcome trials.

What this study cannot tell us

This is a perspective article, not the primary trial publication, so detailed trial data and methodology are not presented. The 14% MACE reduction with oral semaglutide has not been directly compared to injectable semaglutide's cardiovascular benefits. Gastrointestinal side effects may limit real-world adherence more than in the controlled trial setting. The strict dosing requirements (fasting, 30+ minutes before food) may be challenging for many patients. Cost-effectiveness and long-term adherence data are still needed.

How to read the evidence

This is a perspective article discussing the SOUL trial, a randomized controlled cardiovascular outcome trial. The underlying trial evidence is high quality, but this article is commentary rather than the primary data publication.

When this study was published

Published in 2025, this perspective discusses the recently reported SOUL trial results — among the most important GLP-1 cardiovascular findings since the landmark SUSTAIN-6 and SELECT trials.

The bigger picture

The evolution from injectable to oral GLP-1 drugs mirrors a broader trend in peptide therapeutics toward more patient-friendly formulations. Oral semaglutide overcomes the absorption challenge of peptide drugs in the gut through a co-formulated absorption enhancer (SNAC). If oral GLP-1 drugs can match injectable outcomes, this technology platform could eventually be applied to other peptide hormones, making an entire class of treatments more accessible.

Questions still open

Is the 14% MACE reduction with oral semaglutide comparable to what injectable semaglutide achieves in similar populations?
Will real-world adherence to the strict oral dosing requirements match what was seen in the SOUL trial?
Could next-generation oral GLP-1 formulations eliminate the fasting requirement and improve adherence?

Common questions

Can you take semaglutide as a pill instead of an injection?

Yes — oral semaglutide (Rybelsus) is available as a daily pill. The SOUL trial confirmed that this oral form reduces cardiovascular events by 14% in high-risk diabetes patients, similar to the heart protection seen with injectable GLP-1 drugs. The trade-off is strict dosing rules: it must be taken on an empty stomach with minimal water, at least 30 minutes before eating or taking other medications.

Is oral semaglutide as effective as injectable semaglutide for the heart?

The SOUL trial showed a 14% reduction in major cardiovascular events with oral semaglutide, which is in the same range as injectable GLP-1 drugs. However, no head-to-head trial has directly compared oral versus injectable semaglutide for cardiovascular outcomes. The oral form provides a real option for patients who need cardiovascular protection but are unwilling or unable to take injections.

Read the original research

Oral Semaglutide: A Step Forward in Cardiovascular Risk Management for Type 2 Diabetes.

Cardiovascular & hematological disorders drug targets, 25(4), 227-230

View on PubMed ↗Publisher’s paper ↗

Citation

Luna-Ceron, Eder; Kattamuri, Lakshmi; Duvvuru, Sparsha Reddy; Mukherjee, Debabrata. (2025). Oral Semaglutide: A Step Forward in Cardiovascular Risk Management for Type 2 Diabetes.. Cardiovascular & hematological disorders drug targets, 25(4), 227-230. https://doi.org/10.2174/011871529X421551250801194823